Pfizer's $7.3B Metsera Deal Aims to Trim Lilly & Novo’s Lead in Obesity Race

Cheddar News

Pfizer is acquiring weight-loss drug developer Metsera in a deal valued at up to $7.3 billion as it tries to catch up in the booming obesity treatment market.

Transcript

00:00Pfizer is acquiring weight loss drug developer Metzera in a deal valued at up to $7.3 billion

00:06as it scrambles to catch up in the booming obesity treatment market.

00:11The move comes after Pfizer's own obesity drug hit regulatory roadblocks,

00:15including concerns about liver damage.

00:17Metzera is developing hormone-based oral and injectable therapies

00:21aimed at offering more flexible dosing options.

00:24Following the news, Metzera's shares jumped over 60% in pre-market trading.

00:29Metzera's shares jumped over 60% in pre-market trading.

Category

Transcript

Comments

Recommended